A software startup has sued Epic on antitrust grounds, arguing that the electronic health records giant has orchestrated a ...

A Johnson & Johnson subsidiary filed for bankruptcy in its third attempt to settle a vast majority of cases alleging its talc ...

As the federal government is threatening Johnson & Johnson with fines related to its unilateral alterations to the 340B drug ...

Biohaven is seeking to reverse the fate of its embattled experimental drug troriluzole in spinocerebellar ataxia — a ...

UCB’s Bimzelx scored three more FDA approvals on Monday, making it the first and only IL-17A and IL-17F inhibitor approved in ...

Plus, news about Longevity Biomedical, Sensorion, Teva and Bristol Myers Squibb: Context Therapeutics buys a T cell engager: The biotech will pay $15 million upfront and up to $118.5 million in ...

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...

For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and ...

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...